Is CJC-1295 with GHRP-2 legal in Australia?

A 10 mg vial split evenly between a GHRH analogue and a ghrelin-receptor agonist. The pairing of those two drug classes has genuine human data, including a study in which combining them drove more growth hormone than either alone, but that work used different agents, given intravenously or by pump, in a clinic. No study has tested this vial.

This is the oldest rationale in the growth hormone corner of the peptide market: hit the pituitary from two directions at once. A GHRH analogue raises the size of a pulse, a ghrelin-receptor agonist triggers one and blunts somatostatin, and the two together do more than either.

Mechanism: Two receptors, one axis. The GHRH analogue binds the GHRH receptor on pituitary somatotrophs and increases the amplitude of a growth hormone pulse.

Regulatory history: Not approved. Neither component is an approved medicine in the United States, and the combination has never been evaluated.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for CJC-1295 with GHRP-2 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.